Eli Lilly and Company Stock Price, News, Quote & History

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Company

Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact

Lilly's Omvoh approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Lilly declares fourth-quarter 2025 dividend

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea

Lilly's Omvoh demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis

Lilly to Acquire Adverum Biotechnologies

Lilly's Verzenio® prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

5 Small-cap Biotech ETFs to Watch in 2025

5 Biggest Pharma Stocks in 2025

Top 5 Small-cap Pharma Stocks of 2025

5 Biggest Pharmaceutical ETFs in 2025

5 US Longevity and Anti-aging Stocks to Watch in 2025

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Latest News

Panoro Minerals Ltd. Announces Brokered LIFE Offering for Gross Proceeds of up to C$5 Million

Electra Names Paolo Toscano Vice President, Projects and Engineering to Oversee Construction of North America's First Cobalt Sulfate Refinery

Exploits Announces Results of Annual General and Special Meeting

ADP Reports First Quarter Fiscal 2026 Results

European Commission Approves KEYTRUDA® as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Expressing PD-L1

Latest News

Outlook Reports world

Featured Stocks

Browse Companies